(Q48825323)

English

Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.

scientific article published on 29 April 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/20428874

Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/20428874

0 references

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Ourania Katopodis

1

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/20428874

Aris Polyzos

2

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/20428874

Nikolaos Kentepozidis

3

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/20428874

Stylianos Giassas

4

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/20428874

Maria Rovithi

5

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/20428874

Vasiliki Bozionelou

6

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/20428874

Kostas Kalbakis

7

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/20428874

Lambros Vamvakas

8

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/20428874

Dimitris Mavroudis

9

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/20428874

Vassilis Georgoulias

10

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/20428874

publication date

29 April 2010

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/20428874

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/20428874

67

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/20428874

2

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/20428874

361-368

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/20428874

https://scigraph.springernature.com/pub.10.1007/s00280-010-1329-6

0 references

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1329-6

21 January 2018

Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1329-6

21 January 2018

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1329-6

21 January 2018

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1329-6

21 January 2018

Short time to progression under first-line chemotherapy is a negative prognostic factor for time to progression and residual survival under second-line chemotherapy in advanced pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1329-6

21 January 2018

Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1329-6

21 January 2018

Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1329-6

21 January 2018

Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1329-6

21 January 2018

Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1329-6

21 January 2018

A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1329-6

21 January 2018

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1329-6

21 January 2018

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1329-6

21 January 2018

Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1329-6

21 January 2018

Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1329-6

21 January 2018

Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1329-6

21 January 2018

Phase II trial of oral rubitecan in previously treated pancreatic cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1329-6

21 January 2018

Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1329-6

21 January 2018

Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1329-6

21 January 2018

A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1329-6

21 January 2018

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1329-6

21 January 2018

Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1329-6

21 January 2018

Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1329-6

21 January 2018

Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1329-6

21 January 2018

The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1329-6

21 January 2018

Identifiers

10.1007/S00280-010-1329-6

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/20428874

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/20428874

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48825323&oldid=1577693200"